Adjuvant Bevacizumab for Triple-Negative Breast Cancer

Numerous strategies have been investigated to reduce the risk for recurrence of early-stage, triple-negative breast cancer (TNBC). Because TNBC lacks estrogen receptor, progesterone receptor, or human epidermal growth factor receptor 2 therapeutic targets, novel approaches have been evaluated, including the use of anti-angiogenic agents. Bevacizumab, a monoclonal antibody directed against vascular endothelial growth factor A had been FDA-approved and widely used to treat patients with metastatic breast cancer, but re-evaluation of clinical trial results, which failed to demonstrate effectiveness, led to withdrawal of the approval. Since then, multiple clinical trials had been launched to evaluate bevacizumab in the neoadjuvant and/or adjuva…